Sample Scenario — Executive Misconduct & Reputational Crisis Simulation

The Ashby Ridge Leadership Crisis Exercise

A branching, choose-your-path tabletop built for a publicly traded regional bank. No systems fail and no data is lost — the crisis is the person at the top of the escalation chain. Six shared injects establish the allegations, then the board's own decision — put the CEO on leave, or keep him in role — sends the exercise down one of two independent, fully-scripted paths. Neither one protects the board from scrutiny.

16injects per path
2diverging paths
10 dayssimulated timeline
3.5 hrstypical runtime

Fictional, but built to feel real in the room.

Every detail below is fictional — specific enough to feel real in the room, and generic enough to map onto almost any organization where one leader's reputation has become the company's reputation.

Ashby Ridge Financial

A NYSE-listed regional bank holding company headquartered in Minneapolis, with $31B in assets, 210 branches across five states, and ~4,800 employees. Eleven years ago it was a struggling thrift; today it is one of the best-performing banks in its peer group, and analysts credit almost all of that to the CEO who led the turnaround.

Ashby Ridge is four months into its largest acquisition yet — a pending purchase of Lakeshore Community Bank that still needs regulatory approval. The deal, the stock, and the strategy all run through one person. Which is exactly why an allegation about that person is a crisis for the whole institution.

The CEO — 11 years in role, architect of the turnaround
The Independent Chair — former regulator, 3 years on the board
Halvorsen Capital — largest shareholder, 9% stake
Lakeshore Community Bank — pending acquisition, awaiting approval

The crisis everyone faces.

Six injects, delivered over the first 42 hours, that every player experiences regardless of what the board ultimately decides. This phase ends with the decision that splits the exercise in two.

DAY 0
15:20
INJECT 1Detection

"We're publishing in 48 hours"

A reporter at a national business outlet emails Ashby Ridge's head of communications. A former executive vice president of commercial banking alleges the CEO harassed her and then forced her out after she complained. The story runs in two days, and the reporter wants comment by 5 p.m. tomorrow.

Tests: who gets told, and in what order, when the allegation is about the person at the top of the escalation chain.
19:00
INJECT 2History

The file nobody showed the board

The general counsel pulls the records. The executive filed an internal complaint fourteen months ago. It was reviewed by an HR team reporting to the CEO's chief of staff and closed as unsubstantiated. Three months later she left with a $1.2M separation agreement and a non-disclosure clause, approved by the CEO. The board's compensation committee was never told.

Tests: recognizing when the company's own process is part of the story — not just the allegation.
DAY 1
08:30
INJECT 3Governance

"Handle it"

The CEO denies everything. He calls the former executive a disgruntled low performer, wants to issue a forceful denial before the story runs, and asks the general counsel — his direct report — to threaten the outlet with a defamation suit.

Tests: whether the general counsel and the board recognize the conflict — and settle who the company's lawyers actually work for.
12:00
INJECT 4Internal

The building already knows

The reporter tells communications that two current employees have contacted her with similar accounts. Meanwhile, a post on an anonymous workplace app — "Is the story about our CEO finally coming out?" — has hundreds of replies from people listing Ashby Ridge as their employer.

Tests: internal communications when employees seem to know more than the board does.
17:00
INJECT 5Board / regulatory

The board convenes without him

The independent chair calls an emergency session of the independent directors. Outside counsel recommends forming a special committee and retaining an independent investigator. The Lakeshore application is still pending, and the bank's regulatory relationship manager has a routine call on the calendar for Day 3.

Tests: whether the board takes ownership of the response — committee, counsel, investigator — rather than waiting for management to bring it a plan.
DAY 2
09:00
INJECT 6Decision point

On leave, or in the chair

The story publishes in 30 hours. Outside counsel lays out two options: place the CEO on leave pending the independent investigation, with the CFO as interim CEO; or keep him in role, walled off from anything touching the investigation. Halvorsen Capital has privately called the chair to back the CEO. Several directors worry that leave will look like a verdict. The board has to decide.

Tests: governance judgment under incomplete facts — protecting the process without prejudging the outcome. This is the fork.

The board decides. The exercise branches.

INJECTS 1–6 DECISION A — CEO ON LEAVE B — CEO STAYS

From here, the facilitator runs one of two fully independent scripts depending on what the board chose in Inject 6. Toggle between them below to see how each one unfolds — in a live session, players only ever see the one they earned.

Path A — the board places the CEO on leaveTen injects. Leave protects the investigation, not the institution — and it hands the board a company it has never actually run.
DAY 2
18:00
INJECT 7AAnnouncement

"A rush to judgment"

Ashby Ridge announces that the CEO is on leave pending an independent review, with the CFO serving as interim CEO. Within an hour, the CEO's personal lawyer calls the decision a rush to judgment and notes that his employment agreement allows him to resign for "good reason" if his duties are materially reduced.

Tests: whether the announcement language protects the process without implying guilt — and whether anyone read the employment agreement first.
DAY 3
09:30
INJECT 8AMarket

Down 14%, and the largest holder is angry

The stock opens down 14%. Analysts question whether the Lakeshore deal survives without its architect. Halvorsen Capital issues a public statement criticizing the board for "sidelining proven leadership on the strength of a newspaper story."

Tests: investor communications when the board can't share the facts behind its own decision.
14:00
INJECT 9ARegulatory

The routine call isn't routine

The regulatory relationship manager asks who is running the bank, whether the Lakeshore integration plan depended on the CEO personally, and when the board first learned of the original complaint. She requests the minutes of every board meeting held since Day 0.

Tests: candor with a regulator about what the board knows, what it doesn't, and what it should have known earlier.
DAY 4
10:00
INJECT 10ALeadership vacuum

An interim CEO without the keys

Two senior executives loyal to the CEO tell the interim CEO they're considering resigning. Then treasury flags a problem: the bank's delegations of authority still name the CEO for approvals above $50M, and a large credit decision is due Friday.

Tests: whether succession is a plan on paper or an operating reality — authority, signatures, and loyalty included.
DAY 5
07:45
INJECT 11ACounter-narrative

He won't stay quiet

The CEO gives an interview defending his record. He references the former executive's performance reviews by name — confidential personnel information he still had access to. Her lawyer calls it textbook retaliation, on the record.

Tests: managing a leader on leave who is still an officer, still a shareholder, and still talking — and the company's exposure for what he says.
DAY 6
16:00
INJECT 12AInvestigation

The investigation finds something else

The independent investigators report a second issue: over three years, the CEO used the company aircraft for personal trips that were never reported as perquisites in the proxy statement. It's now a securities disclosure question as well as a conduct question.

Tests: handling investigation scope creep — and whether new findings trigger their own disclosure obligations.
DAY 7
11:00
INJECT 13AEmployees

"Will you release us from our NDAs?"

At an all-hands meeting, the interim CEO is asked whether other employees were paid to stay silent — and whether the board will release former employees from their non-disclosure agreements. The question is recorded and posted online within the hour.

Tests: making a values decision in public, with legal, cultural, and precedent consequences pulling in different directions.
DAY 8
13:00
INJECT 14AStrategic

Lakeshore wants to talk price

Lakeshore Community Bank's board sends a letter citing "material uncertainty in the acquirer's leadership" and asks to reopen deal terms. Its CEO tells reporters only that his board is "evaluating all options."

Tests: connecting a reputational crisis to its strategic cost — and who negotiates for a company with an interim CEO.
DAY 9
09:00
INJECT 15ADecision point

The findings are mixed

The investigators' interim findings: the harassment allegation can't be fully corroborated, but the retaliation, the concealed settlement, and the aircraft use are substantiated. The board must choose — terminate for cause and fight the contract claims, negotiate a quiet departure, or reinstate the CEO with conditions. The board has to decide.

Tests: whether the board can decide on what's been proven rather than what's been alleged — and own the outcome either way.
DAY 10
10:00
INJECT 16AAccountability

Now the board is the story

A proxy advisory firm recommends voting against the compensation committee chair at the next annual meeting, asking why no director knew about a $1.2M settlement with a senior executive. Reporters start asking the same question.

Tests: separating the end of the CEO question from the start of the board's own accountability — and fixing the reporting line that failed.
Path B — the board keeps the CEO in roleTen injects. Keeping him buys stability, not independence — and every new fact gets measured against the board's original statement of confidence.
DAY 2
18:00
INJECT 7BStatement

"Full confidence"

Ashby Ridge announces a special committee and independent investigation, and says the board has "full confidence" in the CEO, who will recuse himself from investigation matters. The story publishes the next morning with that statement in the fourth paragraph.

Tests: whether "full confidence" quietly prejudges the investigation the board just launched.
DAY 3
08:00
INJECT 8BFollow-up

"Did the board know?"

The reporter's follow-up names the $1.2M separation payment and the NDA and asks a single question: did the board know? It didn't. The answer either way is a headline.

Tests: the board responding truthfully to facts about its own oversight, not just about the CEO.
16:00
INJECT 9BEmployees

Three hundred signatures

An open letter signed by more than 300 employees asks the board to place the CEO on leave until the investigation concludes. By evening, it's been shared with the reporter.

Tests: internal legitimacy — how the board answers its own workforce without reversing itself under pressure or ignoring the message.
DAY 4
11:00
INJECT 10BRegulatory

Independent on paper

The regulatory relationship manager asks how an investigation can be independent when the CEO still oversees the general counsel, HR, and the systems that hold the evidence. She asks for written confirmation of document preservation measures by Friday.

Tests: whether investigation independence holds up in practice — reporting lines, data access, and evidence custody included.
DAY 5
14:30
INJECT 11BEvidence

Messages deleted on Day 0

The investigators' forensic review shows that the CEO's chief of staff deleted a set of messages from a company phone the evening the reporter's email arrived. It's unclear who asked her to — or whether anyone did.

Tests: escalation when an investigation surfaces possible obstruction — and the board's tolerance for the CEO staying in role.
DAY 6
06:00
INJECT 12BMedia

A second account, on the record

A second former employee goes on the record in a follow-up story, describing similar conduct and a similar exit. The article quotes the board's "full confidence" statement in its opening paragraph.

Tests: changing position when the facts change — without making the first position look indefensible.
DAY 7
10:00
INJECT 13BCommercial

The money starts to move

A city treasury office pauses new deposits "pending review of governance concerns," and a state pension fund sends a letter questioning board oversight. Commercial bankers report clients asking whether the bank is stable.

Tests: stakeholder communications as reputational damage turns into commercial damage.
DAY 8
19:00
INJECT 14BBoard conflict

A board divided

The independent chair now wants the CEO on leave. Two long-tenured directors refuse, arguing that reversing course now would be an admission. A third director drafts a resignation letter that would cite "governance failures" publicly.

Tests: whether a divided board can still reach a decision — and what happens when a director's exit becomes its own disclosure.
DAY 9
09:00
INJECT 15BDecision point

The largest shareholder changes sides

Halvorsen Capital, the CEO's strongest backer on Day 2, now publicly demands his departure and two new independent directors, and threatens a proxy contest. The board faces the decision it declined a week ago — remove the CEO before the investigation concludes — on far worse terms. The board has to decide.

Tests: whether the room learned from its first decision, or simply repeats it under heavier pressure.
DAY 10
15:00
INJECT 16BStrategic

The deal waits on the board

The regulator signals that the Lakeshore application won't move forward until management and governance questions are resolved. Lakeshore agrees to extend its deadline once, for 60 days. The CEO question can be settled in a week; rebuilding the board's credibility will take far longer.

Tests: separating immediate relief from the longer governance repair the institution actually needs.

What the debrief surfaces.

The two paths are built to converge on the same hard questions, arrived at from opposite directions.

If the board placed the CEO on leave

  • Did the announcement protect the investigation without reading as a verdict — and who reviewed the employment agreement before it went out?
  • Were succession and delegations of authority ready to work in hours, or only on paper?
  • How did the board manage an executive on leave who still had access, standing, and a platform?

If the board kept the CEO in role

  • Was the investigation's independence real — who controlled the lawyers, HR, and the evidence?
  • What did "full confidence" cost the board once the facts started to change?
  • Why did a $1.2M settlement with a senior executive never reach the board — and is that reporting line fixed now?
Ashby Ridge Financial, Halvorsen Capital, Lakeshore Community Bank, and all individuals described in this scenario are fictional and created for exercise purposes only.

Want this as a PDF?

The full Ashby Ridge scenario — every inject, both paths, and the debrief questions — is available as a print-ready PDF you can share with your own team or board. Enter your email and we'll take you straight to the download.

This is one scenario. Yours would be built around your business.

The Ashby Ridge exercise is a sample — built to show how a leadership crisis simulation can branch on the decision that actually matters, and stay uncomfortable in both directions. A simulation built for your organization starts with your governance, your escalation paths, and your board.

Confidential by design

Exercises often require access to crisis plans, escalation structures, and vulnerabilities. That material is handled in confidence, and NDAs are available on request.

Talk to us about a custom simulation →